News stories about Karyopharm Therapeutics (NASDAQ:KPTI) have trended somewhat positive on Thursday, according to Alpha One Sentiment Analysis. Alpha One, a subsidiary of Accern, identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of 0.15 on Alpha One’s scale. Alpha One also assigned media coverage about the company an impact score of 71 out of 100, meaning that recent press coverage is likely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected AlphaOne Sentiment’s scoring:
- Karyopharm Therapeutics Inc. (KPTI): A Detailed Look at its Institutional Ownership – Post Analyst (postanalyst.com)
- Hot Stocks Report: MGIC Investment Corporation (MTG), Karyopharm Therapeutics Inc. (KPTI) – Post Analyst (postanalyst.com)
- Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : April 12, 2017 (finance.yahoo.com)
- Comcast Corporation (NASDAQ:CMCSA) opened its 5000-square-foot Xfinity Store (eleganthomesinla.com)
- Karyopharm Therapeutics Inc (KPTI) Given “Buy” Rating at Jefferies Group LLC (americanbankingnews.com)
A number of equities research analysts have recently issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, March 3rd. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, April 5th. Robert W. Baird reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a research note on Tuesday, March 7th. Finally, Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and an average price target of $13.96.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 3.89% during midday trading on Thursday, reaching $10.96. 229,992 shares of the company’s stock traded hands. The company’s market capitalization is $459.23 million. The company has a 50-day moving average of $11.17 and a 200-day moving average of $9.95. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, March 16th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). Equities research analysts anticipate that Karyopharm Therapeutics will post ($2.76) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Likely to Effect Karyopharm Therapeutics (KPTI) Share Price” was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at http://sleekmoney.com/somewhat-positive-press-coverage-likely-to-effect-karyopharm-therapeutics-kpti-share-price/1739589.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/somewhat-positive-press-coverage-likely-to-effect-karyopharm-therapeutics-kpti-share-price/1739589.html
Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.